How should a patient on Wellbutrin (bupropion) 300 mg daily for depression be tapered off the medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tapering Wellbutrin 300 mg for Depression

For a patient on Wellbutrin (bupropion) 300 mg daily for depression, reduce to 150 mg once daily for 1-2 weeks before complete discontinuation. 1

FDA-Approved Tapering Protocol

The FDA label for bupropion extended-release explicitly states: "When discontinuing treatment in patients treated with bupropion hydrochloride extended-release tablets (XL) 300 mg once daily, decrease the dose to 150 mg once daily prior to discontinuation." 1

This is the only FDA-specified tapering instruction for bupropion and should be followed as the standard approach. 1

Recommended Timeline

Week 1-2: Reduce from 300 mg to 150 mg once daily in the morning 2, 1

Week 3: Discontinue completely after tolerating 150 mg for 1-2 weeks 2

The 150 mg dose represents a sub-therapeutic maintenance level for depression (standard therapeutic dose is 300 mg), making it an appropriate intermediate step before complete cessation. 2

Why Bupropion Requires Less Aggressive Tapering

Unlike SSRIs, bupropion's mechanism of dopamine/norepinephrine reuptake inhibition produces less severe withdrawal syndromes than serotonergic agents. 2 The standard NCCN dosing demonstrates that bupropion tolerates relatively rapid dose transitions—it can be initiated at 150 mg and increased to 300 mg after just 3 days, suggesting forgiving pharmacokinetics. 2

General antidepressant discontinuation guidelines recommend 10-14 days for tapering, and bupropion's unique mechanism makes it less prone to withdrawal syndromes compared to SSRIs. 2

Monitoring for Withdrawal Symptoms

While uncommon, watch for:

  • Irritable mood 3
  • Anxiety 3
  • Sleeplessness 3
  • Headache 3
  • Generalized aches and pains 3

These symptoms have been reported with abrupt bupropion discontinuation, reinforcing the importance of gradual tapering. 3

Special Consideration: Depression Symptom Rebound

Highly nicotine-dependent smokers treated with bupropion experience decreased depressive symptoms during active treatment but may experience rebound depression when bupropion is discontinued. 4 While this study focused on smoking cessation, the principle applies to depression treatment—monitor closely for mood deterioration after discontinuation. 4

If Withdrawal Symptoms Emerge

For patients experiencing withdrawal symptoms during the standard taper, consider:

  • Extending the 150 mg phase to 4-6 weeks before discontinuation 2
  • Alternating 150 mg daily with 150 mg every other day for 1-2 weeks before complete cessation 2

Critical Safety Points

  • Never stop abruptly from 300 mg—always step down to 150 mg first 1
  • Educate patients about potential withdrawal symptoms and the benefits of compliance 3
  • Reassess the need for continued antidepressant treatment before discontinuation 1
  • If depression symptoms worsen during tapering, consider maintaining treatment rather than forcing discontinuation 1

Comparison to Other Antidepressants

SSRIs require much more gradual, hyperbolic tapering down to doses far below therapeutic minimums to minimize withdrawal. 5 Bupropion's simpler two-step taper (300→150→0) over 2-3 weeks contrasts sharply with SSRI tapers that may require months and exponential dose reductions. 5, 6

References

Guideline

Tapering Bupropion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Bupropion-Associated Withdrawal Symptoms: A Case Report.

Primary care companion to the Journal of clinical psychiatry, 1999

Research

Effect of bupropion on depression symptoms in a smoking cessation clinical trial.

Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 2004

Research

Clinical management of antidepressant discontinuation.

The Journal of clinical psychiatry, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.